Phase 3 Study Investigating Ibrutinib In Younger CLL Patients

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, Discusses Phase 3 Study Investigating Ibrutinib In Younger CLL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com